U.S. Capital Markets Stock News

NYSE:UBER
NYSE:UBERTransportation

Uber Reshapes Leadership As Investors Weigh Culture, Safety And Valuation

Uber Technologies (NYSE:UBER) has announced a new leadership structure. Jill Hazelbaker has been appointed President and Chief Corporate Affairs Officer. The role consolidates oversight of human resources, corporate affairs, and safety operations. The change follows the departure of Chief People Officer Nikki Krishnamurthy. For investors watching Uber Technologies at a share price of $75.09, this executive reshuffle comes at a time when the stock has had mixed recent returns. The share...
NYSE:FDS
NYSE:FDSCapital Markets

FactSet Research Systems (FDS) Valuation Check After Mixed Share Performance And Underappreciated Platform Transition

Recent performance snapshot FactSet Research Systems (FDS) has come under pressure recently, with the stock down over the past month and year to date, while still showing a modest gain over the past 3 months. That mixed share performance sits alongside annual revenue of US$2.4b and net income of US$587.8m, as investors weigh the company’s role as a financial data and analytics platform serving asset managers, banks, and other investment professionals worldwide. See our latest analysis for...
NYSE:JNJ
NYSE:JNJPharmaceuticals

Assessing Johnson & Johnson (JNJ) Valuation After Earnings Beat Guidance Hike And Ongoing Dividend Growth

Johnson & Johnson (JNJ) just reported quarterly earnings and sales ahead of expectations, supported by both its Innovative Medicines and MedTech segments, while raising 2026 guidance and extending its dividend growth streak to 64 years. See our latest analysis for Johnson & Johnson. Despite the earnings beat and steady dividend record, the stock is trading at US$226.71, with the share price down 5.01% over 30 days and 6.88% over 90 days. The 1-year total shareholder return of 53.99% and...
NYSE:O
NYSE:ORetail REITs

Is Realty Income’s Q1 Beat and Capital Raise Altering The Investment Case For Realty Income (O)?

Earlier in May 2026, Realty Income reported higher first-quarter revenue of US$1,548.73 million and net income of US$311.77 million year over year, modestly lowered full-year 2026 net income per-share guidance, and completed US$99.3 million of share repurchases alongside fresh follow-on and at-the-market equity offerings. The company also advanced its private capital and acquisition agenda by completing a US$1.70 billion cornerstone capital raise, lifting full-year investment guidance to...
NasdaqGS:CECO
NasdaqGS:CECOMachinery

A Look At CECO Environmental (CECO) Valuation After Recent Share Price Momentum

Why CECO Environmental Stock Is On Investors’ Radar CECO Environmental (CECO) has caught investor attention after a strong share price run, with the stock up about 25% over the past month and about 2% over the past 3 months. See our latest analysis for CECO Environmental. That recent 25% 1 month share price return comes after a quieter 3 month move and sits alongside a 35% year to date share price gain and a very large 5 year total shareholder return. Together, these point to strong longer...
NasdaqGS:JD
NasdaqGS:JDMultiline Retail

JD.com (JD) Is Up 6.2% After Big Buyback and Mixed Q1 Earnings - What's Changed

Earlier this week, JD.com reported first-quarter 2026 results showing revenue of CNY 315.69 billion and net income of CNY 5.10 billion, with earnings per share from continuing operations roughly halving year on year. At the same time, JD.com completed a major buyback program repurchasing 227.70 million shares, about 15.87% of its share base, signaling management’s confidence while it invests in automation, AI logistics, and higher-margin services. Next, we’ll examine how JD.com’s strong Q1...
NYSE:INGR
NYSE:INGRFood

Ingredion Tate And Lyle Talks Test Growth Story And Execution Risks

Ingredion (NYSE:INGR) has entered takeover talks to acquire Tate & Lyle in an all cash deal. The potential transaction is valued at about US$3.7b and would combine two major players in sweeteners and specialty food ingredients. The discussions confirm a formal approach, although there is no announced agreement or timeline for completion. For investors watching NYSE:INGR, this move centers on core products like sweeteners, starches, and specialty ingredients that feed into food, beverage,...
NasdaqCM:AEHR
NasdaqCM:AEHRSemiconductor

Will Mixed Q3 Results And A US$60M Equity Raise Change Aehr Test Systems' (AEHR) Narrative

In the past week, Aehr Test Systems reported mixed fiscal third-quarter 2026 results amid sector uncertainty and recent share dilution from a US$60,000,000 equity offering, while insiders filed and amended several Form 4 and Form 144 disclosures including gifts, sales, and potential resale notices. An interesting angle is that these routine yet sizable insider and equity-related filings are intersecting with questions about AI chip demand strength and company backlog, sharpening investor...
NasdaqGS:APLD
NasdaqGS:APLDIT

Is Applied Digital’s US$7.5 Billion Hyperscaler Lease Reshaping The Investment Case For APLD?

Applied Digital recently closed a US$300 million senior secured bridge facility led by Goldman Sachs to support construction of its third AI data center at the Polaris Forge 1 campus in Ellendale, North Dakota. A separate 15-year, US$7.5 billion lease with an investment-grade U.S. hyperscaler at the Delta Forge 1 campus substantially expands Applied Digital’s contracted revenue base while it retains upside through its ownership stake in the newly formed ChronoScale Corporation. We’ll now...
NasdaqGS:TCBI
NasdaqGS:TCBIBanks

A Look At Texas Capital Bancshares (TCBI) Valuation As Long Term Returns Contrast With Recent Share Price Softness

Recent performance snapshot Texas Capital Bancshares (TCBI) stock has seen mixed returns recently, with the share price near $95.98 and moves that include a decline over the past month and past 3 months, alongside stronger longer term total returns. See our latest analysis for Texas Capital Bancshares. Short term momentum has faded, with the share price down 7.2% over 3 months, yet the 1 year total shareholder return of 26.6% and 3 year total shareholder return of 95.6% show a stronger longer...
NasdaqCM:EGAN
NasdaqCM:EGANSoftware

EGain (EGAN) Q3 41.7% Net Margin Challenges Bearish Earnings Collapse Narrative

eGain (EGAN) has put up a clean Q3 2026 print, with revenue of about US$22.5 million and basic EPS of roughly US$0.09, while the trailing twelve months show revenue of around US$92.2 million and basic EPS of about US$1.41, supported by a very high net profit margin of 41.7% versus 3.3% a year earlier and very large earnings growth over the past year. Over the past few quarters, revenue has ranged from roughly US$21.0 million to US$23.5 million and quarterly basic EPS has moved between about...
NasdaqGS:WIX
NasdaqGS:WIXIT

Is Wixcom (WIX) Now An Opportunity After Sharp Share Price Pullback

If you are wondering whether Wix.com at US$52.71 is starting to look like value or still carries too much risk, the recent share price performance gives you plenty to think about. The stock has fallen 34.4% over the past week, 17.4% over the last month, 47.8% year to date, 71.2% over one year, 34.7% over three years, and 78.7% over five years, which may change how you think about its potential and the risks involved. Recent coverage around Wix.com has focused on how the stock's sharp...
NasdaqCM:ALMU
NasdaqCM:ALMUSemiconductor

Aeluma (ALMU) Q3 Loss Of US$1.8 Million Tests Bullish Profitability Narratives

Aeluma (NasdaqCM:ALMU) has just posted its Q3 2026 numbers, reporting revenue of US$1.2 million and a loss of US$1.8 million, or EPS of US$0.10. This sets a cautious tone for shareholders at the current US$26.65 share price. Over recent quarters the company has reported revenue between US$1.3 million and US$1.6 million, while EPS has shifted from a profit of US$0.12 in Q3 2025 to losses of around US$0.09 to US$0.24 per share. This has kept margins under clear pressure and made profitability...
NasdaqCM:LQDA
NasdaqCM:LQDAPharmaceuticals

Evaluating Liquidia (LQDA) Valuation After Strong Share Price Momentum And YUTREPIA Launch Progress

Recent share performance and business overview Liquidia (LQDA) has drawn fresh attention after recent trading, with the stock’s moves prompting investors to reassess how its rare cardiopulmonary drug portfolio and clinical programs align with their own risk and return expectations. See our latest analysis for Liquidia. Recent trading sits within a much stronger backdrop, with a 30 day share price return of 53.19% and a 1 year total shareholder return of 207.25%. This points to powerful...
NYSE:TMO
NYSE:TMOLife Sciences

Is Thermo Fisher (TMO) Quietly Reinforcing Its End‑to‑End Biopharma Role With New IBTROZI Duties?

Nuvation Bio Inc. recently completed the process technology transfer and product introduction to Thermo Fisher Scientific for IBTROZI (taletrectinib), enabling Thermo Fisher to manufacture the ROS1-positive NSCLC therapy in the United States and support reliable drug supply. Away from the clinic, Thermo Fisher has also been broadening its platform with launches such as the Gibco CTS DynaXS Single Use Bioreactor and Nalgene’s Fresh Flow straw bottle, underscoring its reach from advanced cell...
NYSE:OMF
NYSE:OMFConsumer Finance

A Look At OneMain Holdings (OMF) Valuation After Q1 Earnings Strength And Share Repurchase Completion

Why OneMain Holdings Stock Is Back on Investors’ Radar OneMain Holdings (OMF) has drawn fresh attention after reporting first quarter net income of US$226 million, completing a US$141.58 million buyback tranche, and attracting a 4.8% passive stake from Capital International Investors. See our latest analysis for OneMain Holdings. The recent earnings update and completion of the US$141.58 million buyback come after a period where the share price has fallen 21.89% year to date, even as the 1...
NasdaqGM:AXSM
NasdaqGM:AXSMPharmaceuticals

A Look At Axsome Therapeutics (AXSM) Valuation After AUVELITY Alzheimer’s Agitation Launch Plans And Earnings Update

Axsome Therapeutics (AXSM) is back in focus after detailing plans to launch AUVELITY for Alzheimer’s disease agitation in June, supported by a larger sales force and expectations of broad Medicare Part D coverage. See our latest analysis for Axsome Therapeutics. The June AUVELITY launch plan for Alzheimer’s agitation and recent first quarter 2026 earnings have arrived alongside strong momentum, with a 30 day share price return of 26.11% and a one year total shareholder return of 116.63%. If...
NasdaqCM:SLS
NasdaqCM:SLSBiotechs

SELLAS Nears Key AML Data As Dual Trials Shape High-Risk Outlook

SELLAS Life Sciences Group (NasdaqCM:SLS) is nearing the pivotal Phase 3 data readout for galinpepimut-S in the REGAL trial for acute myeloid leukemia (AML). The company has also initiated a Phase 2 trial of its CDK9 inhibitor SLS009 in newly diagnosed, high-risk AML patients. These clinical milestones mark a key moment for the company’s AML program and broader oncology pipeline. SELLAS Life Sciences Group focuses on late-stage, oncology-focused drug candidates, with galinpepimut-S and...
NasdaqGS:CNXC
NasdaqGS:CNXCProfessional Services

Assessing Concentrix (CNXC) Valuation As AI Concerns And Webhelp Leverage Pressure Investor Sentiment

Concentrix (CNXC) is back in focus as investors weigh its upcoming appearance at the Needham Technology, Media, & Consumer Conference in light of ongoing worries about AI disruption, softer growth trends, and higher leverage from the Webhelp acquisition. See our latest analysis for Concentrix. The recent share price tells a cautious story, with Concentrix at US$23.42 after a 1 month share price return down 17.19% and year to date share price return down 43.17%. This mirrors a 1 year total...
NasdaqCM:TRON
NasdaqCM:TRONLeisure

How Investors Are Reacting To Tron (TRON) Returning To Profitability On Modest Q1 2026 Sales Growth

Tron Inc. reported first-quarter 2026 results, with sales of US$1.18 million versus US$1.09 million a year earlier and net income of US$21.63 million compared with a net loss in the prior-year period. This shift from a loss per share to positive basic earnings per share from continuing operations highlights a sharp improvement in Tron's profitability profile. We will now examine how Tron's return to profitability in the latest quarter shapes the company's broader investment narrative and...
NasdaqGM:OMER
NasdaqGM:OMERPharmaceuticals

Omeros (OMER) Q1 Profit Of US$51.2 Million Tests One Off Gain Narrative

Omeros (OMER) opened 2026 with Q1 revenue of US$9.9 million and basic EPS of US$0.71, alongside net income from continuing operations of US$51.2 million, setting a clear earnings focused tone for the quarter. Over recent periods, the company has seen quarterly revenue move from US$0 to US$9.9 million while quarterly EPS has ranged from a loss of US$0.65 to a gain of US$1.13, giving investors a wide band of outcomes to weigh as they assess how much of the latest profit is repeatable versus...
NasdaqGM:CRML
NasdaqGM:CRMLMetals and Mining

Is Critical Metals (CRML) Quietly Redrawing Western Hafnium Supply Chains With Its Greenland Expansion?

Earlier this month, Critical Metals Corp. received formal approval from the Government of Greenland to acquire a 70% stake in 60 North Greenland ApS, advancing control over key land and assets linked to its Tanbreez rare earth and hafnium project. This approval, together with plans for a Romanian hafnium refinery geared to EU, NATO and US customers, underlines Critical Metals’ role in efforts to reshape Western supply chains for this tightly constrained metal. We’ll now examine how...
NYSE:DOCS
NYSE:DOCSHealthcare Services

Doximity (DOCS) Margin Compression Challenges Bullish AI Growth Narratives After FY 2026 Results

Doximity (DOCS) has just wrapped up FY 2026 with Q4 revenue of US$145.4 million and basic EPS of US$0.10, while trailing twelve month revenue stood at US$644.9 million and EPS at US$1.05. Over recent periods, the company has seen quarterly revenue move between US$138.3 million and US$185.1 million, with basic EPS ranging from US$0.28 to US$0.40, setting the backdrop for a trailing net profit margin that sits at 30.4% versus 39.1% a year earlier. For investors, the latest earnings print is...
NYSE:KNSL
NYSE:KNSLInsurance

How Investors Are Reacting To Kinsale Capital Group (KNSL) Earnings Beat And Higher Dividend Announcement

Kinsale Capital Group recently declared a US$0.25 per-share cash dividend, payable on June 11, 2026 to shareholders of record on May 28, 2026, while also reporting first-quarter 2026 earnings that exceeded analyst expectations. The company’s 10-year streak of dividend increases, including very large dividend growth over the past year, highlights a sustained focus on shareholder returns alongside its specialty excess and surplus insurance operations. We’ll now examine how Kinsale’s...